|
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants Clinical research trials and Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants. Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants clinical trial. Human subjects often receive the most effective healthcare possible for their Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants  Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
For Condition: Graft Rejection,Kidney Disease
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: This protocol facilitates the development of methods for determining whether transplant recipients have developed immune hyporesponsiveness or tolerance towards their allograft. These methods will involve the study of peripheral blood or biopsy tissue obtained at regular intervals from patients receiving kidney or combined kidney-pancreas allografts at the Warren G. Magnuson Clinical Center. In addition, patients that have previously received a kidney or combined kidney-pancreas allograft will be evaluated using assays requiring peripheral blood mononuclear cells and/or biopsies. Assays developed under this protocol will be used in subsequent protocols to assess the effects of immune modulating treatment regimens and may eventually be used to direct clinical care or guide the withdrawal of immunosuppressive agents. However, patients enrolled in this protocol will not have any change in treatment based solely on the assays developed without being enrolled in an additional study.
Details: This protocol facilitates the development of methods for determining whether transplant recipients have developed immune hyporesponsiveness or tolerance towards their allograft. These methods will involve the study of peripheral blood or biopsy tissue obtained at regular intervals from patients receiving kidney or combined kidney-pancreas allografts at the Warren G. Magnuson Clinical Center. In addition, patients that have previously received a kidney or combined kidney-pancreas allograft will be evaluated using assays requiring peripheral blood mononuclear cells and/or biopsies. Assays developed under this protocol will be used in subsequent protocols to assess the effects of immune modulating treatment regimens and may eventually be used to direct clinical care or guide the withdrawal of immunosuppressive agents. However, patients enrolled in this protocol will not have any change in treatment based solely on the assays developed without being enrolled in an additional study.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA Candidates for a kidney or combined kidney-pancreas transplant performed at the Warren G. Magnuson Clinical Center, or non-uremic healthy volunteers who are not on immunosuppressive medications. Previous recipients of kidney or combined kidney-pancreas transplants. Recipients of kidney or combined kidney-pancreas transplants interested in participation in the Recurrent Disease Allograft Registry. Willingness and legal ability to give informed consent, or permission from a legal guardian. Willingness to travel to the Clinical Center for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail. For transplant patients, availability of donor tissue for testing. This could include splenic or peripheral blood lymphocytes from a cadaveric donor or a willing living donor enrolled on the Clinical Center Living Donor Protocol who consents to periodic phlebotomy for peripheral blood lymphocyte isolation. EXCLUSION CRITERIA: Inability or unwillingness to comply with protocol monitoring and therapy, including, among others, a history of noncompliance, circumstances where compliance with protocol requirements is not feasible due to living conditions, travel restrictions, access to urgent medical services, or access to anti-rejection drugs after the research protocol is completed. Any active malignancy. Patients with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing these are appropriately eliminated prior to transplant. Significant coagulopathy or requirement for anticoagulation therapy that would contraindicate protocol allograft biopsies. Platelet count less than 100,000/mm(3).
Total Enrollment: 9999
Location and Contact Information:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 990119; 99-DK-0119
Study Start Date: June 8, 1999
Record last reviewed: May 28, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001858
Other Graft Rejection Studies:
1. MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery
2. A Study of Zidovudine in HIV-Infected Patients with Kidney Problems
3. Evaluation of New Test Method to Measure Kidney Function
4. Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants
5. Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy
Related Studies:
Other Graft Rejection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
|
|
|
|
|
|
|
|
